TY  - CHAP
M1  - Book, Section
TI  - Medical Therapy of Intermittent Claudication
A1  - Rajachandran, Manu
A1  - Schainfeld, Robert M.
A2  - Dieter, Robert S.
A2  - Dieter, Raymond A.
A2  - Dieter, Raymond A.
PY  - 2009
T2  - Peripheral Arterial Disease
AB  - The  medical  therapy  of  intermittent  claudication  is  founded  on  two  fundamental  precepts  (Table  34-1).  The  most  compelling  of  these  is  that  peripheral  arterial  disease  is  evidence  for  systemic  atherosclerosis.  Affected  patients  most  likely  have  concomitant  coronary  artery  and  cerebrovascular  diseases.  As  a  result,  they  are  at  increased  risk  for  adverse  clinical  outcomes  including  myocardial  infarction,  stroke,  and  death.  These  patients  also  frequently  manifest  symptoms  of  intermittent  claudication,  resulting  in  impaired  functional  status,  or  symptoms  of  critical  limb  ischemia—rest  pain,  ulcers,  or  gangrene,  which  ultimately  threaten  the  viability  of  the  limb.  Therefore,  management  of  these  patients  must  employ  therapeutic  strategies  that  decrease  their  risk  of  cardiovascular  events,  reduce  mortality,  improve  functional  capacity  and  quality  of  life,  and  preserve  limb  integrity.  In  contrast  to  the  relative  intangibility  of  vascular  risk  reduction,  symptomatic  improvement  in  peripheral  arterial  disease  after  the  institution  of  appropriate  medical  therapy  can  often  become  apparent  to  the  patient  within  a  matter  of  weeks  or  a  few  months  and  can  significantly  enhance  a  patient's  quality  of  life.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/19
UR  - accesscardiology.mhmedical.com/content.aspx?aid=1127168446
ER  -